import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-respiratory-market-report';

/**
 * Curated copy for the UAE respiratory programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 251M 2026 → ~USD 388M 2030, ~13.6% CAGR).
 * Detail: MOHAP/DHA/DOH access, insurer coverage, asthma biologics, dust/air-quality burden; epidemiology cited as published ranges.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_RESPIRATORY_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Respiratory Market Report 2026',
  metaTitle: 'UAE Respiratory Market Report 2026 | BioNixus',
  metaDescription:
    'UAE respiratory market ~USD 251M in 2026 (BioNixus analysis), ~13.6% CAGR: MOHAP/DHA/DOH access, insurer prior authorization for asthma biologics (dupilumab, mepolizumab), COPD therapy, dust-driven burden—decision-ready Gulf intelligence.',
  heroLead:
    'This briefing reads UAE respiratory care through its insurance logic: an asthma and allergic-disease burden amplified by dust and air quality, an affluent insured population that adopts biologics quickly where covered, and emirate-level prior-authorization rules—across MOHAP, DHA, and DOH—that decide whether severe-asthma therapy is reimbursed.',
  summaryPara1:
    'Respiratory disease in the UAE is shaped by a high asthma and allergic-rhinitis burden, a hot and dust-exposed environment, rising COPD, and a large, insured, expatriate-rich population. BioNixus sizes the respiratory market at roughly USD 251 million in 2026, advancing toward about USD 388 million by 2030 at roughly 13.6% CAGR. The inhaled-maintenance base (ICS/LABA, COPD therapy) anchors volume, while severe-asthma biologics for type-2 inflammation—dupilumab, mepolizumab, benralizumab, omalizumab—are the growth and differentiation story. Because most prescribing is insurance-funded, access turns on the three-authority landscape (MOHAP, DHA, DOH) and on mandatory-insurance prior-authorization and biomarker criteria that differ by emirate and payer. Sizing reflects BioNixus market analysis, 2026.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [UAE immunology & biologics market report](/market-reports/uae-immunology-biologics-market-report) for the shared type-2/biologic budget logic, the [GCC respiratory market report](/market-reports/gcc-respiratory-market-report) for Gulf-wide benchmarking, the [Saudi Arabia respiratory market report](/market-reports/saudi-arabia-respiratory-market-report) for the larger neighbouring market, [respiratory therapy research](/healthcare-market-research/therapy/respiratory) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'Mandatory-insurance prior authorization and biomarker criteria (blood eosinophils, IgE, FeNO) for severe-asthma biologics differing by emirate and payer (Thiqa, Daman, Dubai plans); MOHAP registration plus DHA/DOH facility requirements; type-2 inflammation budgets shared with dermatology and ENT via dupilumab cross-indication; dust, heat, and air-quality exacerbation drivers sustaining asthma and COPD burden; premium private pulmonology and allergy centres anchoring biologic initiation; expatriate continuity-of-care and prior-treatment documentation shaping biologic eligibility',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE respiratory as a payer-segmented market layered on an environmental burden. Pulmonologists, allergists, and primary care manage the inhaled base, while severe-asthma biologic access depends on insurer prior authorization, biomarker testing, and emirate-specific medical policy. We pair bilingual specialist quantitative work with insurer and payer-medical-director depth, and we map the type-2 inflammation overlap that puts dupilumab on respiratory, dermatology, and ENT formularies at once. Local realities matter: dust and heat drive exacerbations and seasonal demand, a large expatriate population brings prior-treatment histories that step rules may not recognise, and biologic initiation concentrates in premium private and flagship centres. KOL maps follow real severe-asthma-clinic and referral influence rather than title lists.',
  commercialOutlookParagraph:
    'The outlook to 2030 separates a steady inhaled base from a growing biologic frontier. ICS/LABA and COPD therapy compete on device, formulary, and private-payer cost control; the growth sits in severe-asthma biologics, where IL-5, IL-4Rα, and anti-IgE mechanisms compete and where the type-2 cross-indication story strengthens the value case in an affluent, insured population. Manufacturers should plan emirate-specific prior-authorization strategies, biomarker-testing enablement, and documentation that handles expatriate prior-treatment history, while aligning respiratory and immunology narratives for shared type-2 budgets. Because a small set of insurers and premium centres shapes most biologic volume, share assumptions should be stress-tested by emirate and payer before regional revenue targets are locked.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, and insurer public guidance, plus primary modules—pulmonologist, allergist, and primary-care adoption surveys, insurer and payer medical-policy interviews, and biologic-initiation pathway mapping where data is available. Epidemiology references use published UAE asthma, allergic-disease, and COPD burden ranges as planning inputs, not patient-level forecasts. Because insurer medical policies, biomarker criteria, and facility rules change on short cycles, access statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the UAE respiratory market in 2026?',
      answer:
        'BioNixus market analysis sizes the UAE respiratory market at roughly USD 251 million in 2026, advancing toward about USD 388 million by 2030 at roughly 13.6% CAGR. The inhaled-maintenance base — ICS/LABA combinations and COPD therapy — drives the bulk of volume, while severe-asthma biologics are the fastest-growing and most differentiated segment. Underlying demand reflects a high asthma and allergic-disease burden amplified by dust and air quality, alongside rising COPD in an affluent, insured population that adopts new therapy quickly where it is covered. Because access is insurance-gated, BioNixus treats the figure as a planning band tied to payer policy rather than an audited total. Use the GCC respiratory report for Gulf-wide context, the UAE immunology and biologics report for the shared type-2 budgets, and the UAE healthcare market report for macro sizing.',
    },
    {
      question: 'How do asthma biologics gain access in the UAE?',
      answer:
        'Severe-asthma biologics — dupilumab targeting IL-4Rα, mepolizumab and benralizumab targeting the IL-5 pathway, and omalizumab targeting IgE — require specialist referral, biomarker criteria such as blood eosinophils, IgE, and FeNO, and insurer prior authorization that differs by emirate and payer. MOHAP registration is the entry point, but in practice mandatory-insurance medical policy is the binding constraint on who actually starts therapy. Because dupilumab is also used in atopic dermatitis and chronic rhinosinusitis with nasal polyps, a single type-2 budget is shared across respiratory, dermatology, and ENT, so access cases compete across specialties. BioNixus maps these payer and biomarker gates directly with pulmonologists, allergists, and insurer medical directors, so commercial teams can plan emirate-specific access and anticipate where prior-authorization friction will slow biologic initiation.',
    },
    {
      question: 'How does insurance shape respiratory access across the UAE?',
      answer:
        'Most respiratory prescribing in the UAE is insurance-funded, and coverage rules differ meaningfully across MOHAP, DHA, and DOH plans rather than following one national standard. For the inhaled base, formulary placement and private-payer cost control determine volume; for biologics, prior-authorization and biomarker criteria are decisive and vary by emirate and by payer, including Thiqa, Daman, and the Dubai plans. A large, mobile expatriate population adds continuity-of-care and prior-treatment-documentation challenges when patients change insurers or arrive already established on therapy abroad, and step rules may not recognise that history. BioNixus recommends mapping MOHAP approval, DHA and DOH facility access, and insurer prior-authorization rules per emirate rather than assuming a single national pathway, and revalidating those rules before launch because medical policies are revised frequently.',
    },
    {
      question: 'What environmental factors drive respiratory demand in the UAE?',
      answer:
        'A hot, dusty climate with periodic spikes in airborne particulates sustains a heavy asthma and allergic-rhinitis burden and drives pronounced seasonal exacerbations, while smoking and widespread shisha use contribute materially to COPD. Indoor air-conditioning, occupational dust exposure in construction, and sandstorm episodes add further triggers that are far more prominent than in temperate markets. Together these factors keep both maintenance and rescue-therapy demand structurally high and underpin the growing severe-asthma biologic segment. BioNixus captures these seasonal and environmental dynamics directly in fieldwork, so demand forecasting reflects the UAE’s actual exacerbation patterns and seasonal peaks rather than generic regional assumptions that tend to understate the environmental contribution to respiratory disease in the Gulf.',
    },
    {
      question: 'Which respiratory classes are growing fastest in the UAE?',
      answer:
        'Severe-asthma biologics targeting type-2 inflammation — IL-4Rα blockade with dupilumab, IL-5 and IL-5Rα agents mepolizumab and benralizumab, and anti-IgE omalizumab — are the standout growth segment, reinforced by cross-indication use in atopic dermatitis and chronic rhinosinusitis with nasal polyps that broadens their budget rationale. COPD triple therapy is expanding on the maintenance side as diagnosis improves. The ICS/LABA base remains large but competes mainly on device, formulary placement, and cost rather than novelty. Biomarker-guided prescribing is already well established in the UAE’s premium pulmonology and allergy centres, which concentrate most biologic initiation. BioNixus tracks these class dynamics so teams can prioritise the segments where insured demand and specialist readiness are converging fastest.',
    },
    {
      question: 'How does BioNixus help respiratory teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE respiratory programmes: pulmonologist, allergist, and primary-care adoption studies, insurer and payer medical-policy interviews, severe-asthma biologic access and biomarker-pathway mapping across MOHAP, DHA, and DOH, and KOL mapping tied to real severe-asthma-clinic and referral influence. Deliverables align to launch, biologic-access, or device-defence milestones and connect UAE findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include emirate and payer archetypes, biologic access-risk maps, type-2 cross-indication strategy, and committee-ready executive summaries. We align the respiratory and immunology access narratives where dupilumab and the IL-5/IL-23 agents share a single type-2 budget, since that overlap usually strengthens the value case. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
